Istradefylline 40 mg/day enhanced peak degrees and AUC of CYP3A4 substrates in clinical trials. This outcome was not observed with istradefylline 20 mg/day. Contemplate dose reduction of delicate CYP3A4 substrates.Simply because CYP3A4 inhibition elevates ergotamine and caffeine serum ranges, the risk for vasospasm resulting in cerebral ischemia an